论文部分内容阅读
[目的]本研究探讨成纤维细胞生长因子2型受体(FGFR2)和血管内皮细胞生长因子2型受体(VEG-FR2)在乳腺癌组织中的表达及其临床意义。[方法]应用免疫组化SABC法,检测两种蛋白的表达情况。[结果]FGFR2和VEGFR2在乳腺癌组织中的积分光密度(IOD)表达率平均为分别为78.38±16.4和83.42±18.1。FGFR2、VEGFR2蛋白表达与病理分期和淋巴结转移有关,在乳腺增生病、乳腺癌癌旁组织、乳腺癌中的阳性表达率依次递增(P﹤0.05),而与年龄及分化程度无关。[结论]FGFR2和VEGFR2在乳腺癌中高表达;FGFR2及VEGFR2蛋白的表达强度与乳腺癌病理分期均呈正相关;
[Objective] The purpose of this study was to investigate the expression of fibroblast growth factor type 2 receptor (FGFR2) and vascular endothelial growth factor type 2 receptor (VEG-FR2) in breast cancer and its clinical significance. [Methods] Immunohistochemical SABC method was used to detect the expression of two proteins. [Results] The average optical density (IOD) of FGFR2 and VEGFR2 in breast cancer tissues were 78.38 ± 16.4 and 83.42 ± 18.1, respectively. The expression of FGFR2 and VEGFR2 protein were correlated with pathological stage and lymph node metastasis. The positive rates of FGFR2 and VEGFR2 in breast hyperplasia, paracancer tissues and breast cancer were increased (P <0.05), but not with the age and differentiation degree. [Conclusion] FGFR2 and VEGFR2 are overexpressed in breast cancer. The expression of FGFR2 and VEGFR2 are positively correlated with the pathological stage of breast cancer.